Search Results 1951-1960 of 13645 for Birth Control Palette
... controls without history of cancer. DALY 2.0 USA/ MB-CART2019.1 for DLBCL. Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to ...
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment ...
For people living with epilepsy who have tried various epilepsy treatments to control their seizures with little success, there is another option. It's a ...
Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to ...
placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant ...
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) ...
To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP ...
Learn about clinical trials being conducted at Mayo Clinic to improve the diagnosis, care and outcomes for people with breast conditions.
This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!